- Home
- IRON vs KW Comparison
IRON vs KW Comparison
Compare IRON & KW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- KW
- Stock Information
- Founded
- IRON 2017
- KW 1977
- Country
- IRON United States
- KW United States
- Employees
- IRON N/A
- KW N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- KW Real Estate
- Sector
- IRON Health Care
- KW Finance
- Exchange
- IRON Nasdaq
- KW Nasdaq
- Market Cap
- IRON 1.4B
- KW 1.4B
- IPO Year
- IRON N/A
- KW 1992
- Fundamental
- Price
- IRON $51.61
- KW $6.69
- Analyst Decision
- IRON Strong Buy
- KW Hold
- Analyst Count
- IRON 10
- KW 1
- Target Price
- IRON $93.40
- KW $13.00
- AVG Volume (30 Days)
- IRON 372.4K
- KW 1.1M
- Earning Date
- IRON 08-07-2025
- KW 08-06-2025
- Dividend Yield
- IRON N/A
- KW 7.13%
- EPS Growth
- IRON N/A
- KW N/A
- EPS
- IRON N/A
- KW N/A
- Revenue
- IRON N/A
- KW $514,600,000.00
- Revenue This Year
- IRON N/A
- KW $31.15
- Revenue Next Year
- IRON N/A
- KW $2.98
- P/E Ratio
- IRON N/A
- KW N/A
- Revenue Growth
- IRON N/A
- KW N/A
- 52 Week Low
- IRON $30.82
- KW $5.98
- 52 Week High
- IRON $68.73
- KW $11.88
- Technical
- Relative Strength Index (RSI)
- IRON 56.99
- KW 54.18
- Support Level
- IRON $48.87
- KW $6.48
- Resistance Level
- IRON $54.13
- KW $6.86
- Average True Range (ATR)
- IRON 2.31
- KW 0.18
- MACD
- IRON 0.07
- KW 0.04
- Stochastic Oscillator
- IRON 67.64
- KW 72.66
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About KW Kennedy-Wilson Holdings Inc.
Kennedy-Wilson Holdings Inc is a real estate investment company that owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on multifamily and office properties, as well as industrial and debt investments. It has two business segments; Consolidated Portfolio includes investment activities that involve ownership of multifamily units, office, retail and industrial space, and one hotel, and The Co-Investment Portfolio segment consists of investments the Company makes with partners in which it receives fees, performance allocations that it earns on its fee-bearing capital and distributions and profits from its ownership interest in the underlying operations of its co-investments.